bluebird bio (NASDAQ: BLUE) reported Q1 EPS of $0.21, $0.58 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $6.49 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.